Format
Items per page
Sort by

Send to:

Choose Destination

Search results

Items: 1 to 20 of 233

1.

Sex-specific patterns and differences in dementia and Alzheimer's disease using informatics approaches.

Ronquillo JG, Baer MR, Lester WT.

J Women Aging. 2016 Apr 22:1-9. [Epub ahead of print]

PMID:
27105335
2.

Conversion of external fixation to open reduction and internal fixation for complex distal radius fractures.

Natoli RM, Baer MR, Bednar MS.

Orthop Traumatol Surg Res. 2016 May;102(3):339-43. doi: 10.1016/j.otsr.2016.01.013. Epub 2016 Mar 22.

PMID:
27026500
3.

Rigosertib versus best supportive care for patients with high-risk myelodysplastic syndromes after failure of hypomethylating drugs (ONTIME): a randomised, controlled, phase 3 trial.

Garcia-Manero G, Fenaux P, Al-Kali A, Baer MR, Sekeres MA, Roboz GJ, Gaidano G, Scott BL, Greenberg P, Platzbecker U, Steensma DP, Kambhampati S, Kreuzer KA, Godley LA, Atallah E, Collins R Jr, Kantarjian H, Jabbour E, Wilhelm FE, Azarnia N, Silverman LR; ONTIME study investigators.

Lancet Oncol. 2016 Mar 8. pii: S1470-2045(16)00009-7. doi: 10.1016/S1470-2045(16)00009-7. [Epub ahead of print]

PMID:
26968357
4.

Activation of the Constitutive Androstane Receptor Increases the Therapeutic Index of CHOP in Lymphoma Treatment.

Hedrich WD, Xiao J, Heyward S, Zhang Y, Zhang J, Baer MR, Hassan HE, Wang H.

Mol Cancer Ther. 2016 Mar;15(3):392-401. doi: 10.1158/1535-7163.MCT-15-0667. Epub 2016 Jan 28.

PMID:
26823489
5.

Hydroxylated Dimeric Naphthoquinones Increase the Generation of Reactive Oxygen Species, Induce Apoptosis of Acute Myeloid Leukemia Cells and Are Not Substrates of the Multidrug Resistance Proteins ABCB1 and ABCG2.

Lapidus RG, Carter-Cooper BA, Sadowska M, Choi EY, Wonodi O, Muvarak N, Natarajan K, Pidugu LS, Jaiswal A, Toth EA, Rassool FV, Etemadi A, Sausville EA, Baer MR, Emadi A.

Pharmaceuticals (Basel). 2016 Jan 19;9(1). pii: E4. doi: 10.3390/ph9010004.

6.

Deferasirox therapy is associated with reduced mortality risk in a medicare population with myelodysplastic syndromes.

Zeidan AM, Hendrick F, Friedmann E, Baer MR, Gore SD, Sasane M, Paley C, Davidoff AJ.

J Comp Eff Res. 2015;4(4):327-40. doi: 10.2217/cer.15.20.

PMID:
26274794
7.

Variations in erythropoiesis-stimulating agent administration in transfusion-dependent myelodysplastic syndromes impact response.

Duong VH, Baer MR, Hendrick F, Weiss SR, Sato M, Zeidan AM, Gore SD, Davidoff AJ.

Leuk Res. 2015 Jun;39(6):586-91. doi: 10.1016/j.leukres.2015.03.013. Epub 2015 Mar 28.

PMID:
25869077
8.

c-MYC Generates Repair Errors via Increased Transcription of Alternative-NHEJ Factors, LIG3 and PARP1, in Tyrosine Kinase-Activated Leukemias.

Muvarak N, Kelley S, Robert C, Baer MR, Perrotti D, Gambacorti-Passerini C, Civin C, Scheibner K, Rassool FV.

Mol Cancer Res. 2015 Apr;13(4):699-712. doi: 10.1158/1541-7786.MCR-14-0422. Epub 2015 Mar 31.

9.

Inhibition of IRAK1/4 sensitizes T cell acute lymphoblastic leukemia to chemotherapies.

Li Z, Younger K, Gartenhaus R, Joseph AM, Hu F, Baer MR, Brown P, Davila E.

J Clin Invest. 2015 Mar 2;125(3):1081-97. doi: 10.1172/JCI75821. Epub 2015 Feb 2.

10.

Treatment of Philadelphia chromosome-positive acute lymphoblastic leukemia in pregnancy.

Mainor CB, Duffy AP, Atkins KL, Kimball AS, Baer MR.

J Oncol Pharm Pract. 2016 Apr;22(2):374-7. doi: 10.1177/1078155214568582. Epub 2015 Jan 23.

PMID:
25616656
11.

The FLT3 and PDGFR inhibitor crenolanib is a substrate of the multidrug resistance protein ABCB1 but does not inhibit transport function at pharmacologically relevant concentrations.

Mathias TJ, Natarajan K, Shukla S, Doshi KA, Singh ZN, Ambudkar SV, Baer MR.

Invest New Drugs. 2015 Apr;33(2):300-9. doi: 10.1007/s10637-015-0205-y. Epub 2015 Jan 20.

PMID:
25597754
12.

Patient cost sharing and receipt of erythropoiesis-stimulating agents through medicare part D.

Davidoff AJ, Hendrick FB, Zeidan AM, Baer MR, Stuart BC, Shenolikar RA, Gore SD.

J Oncol Pract. 2015 Mar;11(2):e190-8. doi: 10.1200/JOP.2014.001527. Epub 2015 Jan 6.

13.

Phase I dose escalation study of lestaurtinib in patients with myelofibrosis.

Hexner EO, Mascarenhas J, Prchal J, Roboz GJ, Baer MR, Ritchie EK, Leibowitz D, Demakos EP, Miller C, Siuty J, Kleczko J, Price L, Jeschke G, Weinberg R, Basu T, Pahl HL, Orazi A, Najfeld V, Marchioli R, Goldberg JD, Silverman LR, Hoffman R.

Leuk Lymphoma. 2015;56(9):2543-51. doi: 10.3109/10428194.2014.1001986. Epub 2015 Feb 20.

PMID:
25563429
14.

Expression and prognostic impact of lncRNAs in acute myeloid leukemia.

Garzon R, Volinia S, Papaioannou D, Nicolet D, Kohlschmidt J, Yan PS, Mrózek K, Bucci D, Carroll AJ, Baer MR, Wetzler M, Carter TH, Powell BL, Kolitz JE, Moore JO, Eisfeld AK, Blachly JS, Blum W, Caligiuri MA, Stone RM, Marcucci G, Croce CM, Byrd JC, Bloomfield CD.

Proc Natl Acad Sci U S A. 2014 Dec 30;111(52):18679-84. doi: 10.1073/pnas.1422050112. Epub 2014 Dec 15.

15.

Effect of erythropoiesis-stimulating agent policy decisions on off-label use in myelodysplastic syndromes.

Hendrick F, Davidoff AJ, Zeidan AM, Gore SD, Baer MR.

Medicare Medicaid Res Rev. 2014 Nov 26;4(4). pii: mmrr2014-004-04-a02. doi: 10.5600/mmrr.004.04.a02. eCollection 2014. Erratum in: Medicare Medicaid Res Rev. 2014;4(4). pii: mmrr2014-004-04-a02_corrigendum.

16.

Disparities in black and white patients with multiple myeloma referred for autologous hematopoietic transplantation: a single center study.

Bhatnagar V, Wu Y, Goloubeva OG, Ruehle KT, Milliron TE, Harris CG, Rapoport AP, Yanovich S, Sausville EA, Baer MR, Badros AZ.

Cancer. 2015 Apr 1;121(7):1064-70. doi: 10.1002/cncr.29160. Epub 2014 Dec 2.

17.

High frequency of rare structural chromosome abnormalities at relapse of cytogenetically normal acute myeloid leukemia with FLT3 internal tandem duplication.

Gourdin TS, Zou Y, Ning Y, Emadi A, Duong VH, Tidwell ML, Chen C, Rassool FV, Baer MR.

Cancer Genet. 2014 Oct-Dec;207(10-12):467-73. doi: 10.1016/j.cancergen.2014.09.001. Epub 2014 Sep 16.

PMID:
25441683
18.

Treatment of catheter-related deep vein thrombosis in patients with acute leukemia with anticoagulation.

Oliver N, Short B, Thein M, Duong VH, Tidwell ML, Sausville EA, Baer MR, Kamangar F, Emadi A.

Leuk Lymphoma. 2015 Jul;56(7):2082-6. doi: 10.3109/10428194.2014.982640. Epub 2015 Jan 14.

PMID:
25379622
19.

Lack of objective response of myelodysplastic syndromes and acute myeloid leukemia to decitabine after failure of azacitidine.

Duong VH, Bhatnagar B, Zandberg DP, Vannorsdall EJ, Tidwell ML, Chen Q, Baer MR.

Leuk Lymphoma. 2015 Jun;56(6):1718-22. doi: 10.3109/10428194.2014.966708. Epub 2014 Nov 3.

PMID:
25263320
20.

Prognostic and biologic significance of DNMT3B expression in older patients with cytogenetically normal primary acute myeloid leukemia.

Niederwieser C, Kohlschmidt J, Volinia S, Whitman SP, Metzeler KH, Eisfeld AK, Maharry K, Yan P, Frankhouser D, Becker H, Schwind S, Carroll AJ, Nicolet D, Mendler JH, Curfman JP, Wu YZ, Baer MR, Powell BL, Kolitz JE, Moore JO, Carter TH, Bundschuh R, Larson RA, Stone RM, Mrózek K, Marcucci G, Bloomfield CD.

Leukemia. 2015 Mar;29(3):567-75. doi: 10.1038/leu.2014.267. Epub 2014 Sep 10.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk